Tasly Pharmaceutical Shares Jump After Strong H1 Profit Print
Tasly Pharmaceutical shares rose after the company reported H1 2026 results showing RMB 8.93 billion in net profit attributable to shareholders, a roughly 15.2% year-over-year increase, and an adjusted net profit gain of about 36% excluding non-recurring items. The results outpaced market expectations even as revenue slipped about 2.0% to RMB 42.01…